RAD51 inhibitor / Nerviano Medical Sciences - LARVOL DELTA

Highly potent inhibitors of RAD51, with first-in-class potential, targeting HR-proficient cancers (AACR 2026) - "The novel mechanism of action, with potential for combination with DNA damaging agents and DDR inhibitors, positions Nerviano Medical Sciences' RAD51 inhibitors as promising first-in-class candidates for further development across multiple cancer types resistant to standard of care."

Oncology • Solid Tumor • BRCA2 • HRD • RAD51